pharmaceutical investing Johnson & Johnson's RYBREVANT FASPRO receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
pharmaceutical investing Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo
pharmaceutical investing Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
pharmaceutical investing Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
pharmaceutical investing European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
pharmaceutical investing Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
pharmaceutical investing AbbVie Announces European Commission Approval of RINVOQ® for the Treatment of Adults and Adolescents with Severe Alopecia Areata
pharmaceutical investing AbbVie Announces European Commission Approval of RINVOQ® for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
pharmaceutical investing Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
EnerCom Announces SM Energy as a Keynote Speaker at the 31st EnerCom Denver - The Energy Investment Conference, on August 19, 2026, in Denver, Colorado
